Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Rating of “Buy” from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been assigned a consensus rating of “Buy” from the nine research firms that are currently covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $20.89.

A number of research firms have weighed in on ATEC. Canaccord Genuity Group restated a “buy” rating and issued a $25.00 price target on shares of Alphatec in a research note on Wednesday, March 20th. Stifel Nicolaus decreased their target price on shares of Alphatec from $24.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Alphatec in a research report on Wednesday, May 8th. Barclays initiated coverage on shares of Alphatec in a research report on Monday. They issued an “overweight” rating and a $19.00 price objective for the company. Finally, Piper Sandler dropped their target price on shares of Alphatec from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, May 8th.

Alphatec Price Performance

NASDAQ ATEC opened at $10.96 on Friday. The firm’s 50 day moving average is $10.63 and its 200-day moving average is $13.11. The company has a quick ratio of 1.49, a current ratio of 2.39 and a debt-to-equity ratio of 13.63. The company has a market capitalization of $1.53 billion, a PE ratio of -7.36 and a beta of 1.40. Alphatec has a 12-month low of $8.66 and a 12-month high of $19.14.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $138.48 million during the quarter, compared to analyst estimates of $134.07 million. Alphatec had a negative net margin of 37.45% and a negative return on equity of 1,767.81%. The firm’s quarterly revenue was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. Equities research analysts anticipate that Alphatec will post -1.04 earnings per share for the current fiscal year.

Insider Buying and Selling at Alphatec

In other news, General Counsel Tyson Eliot Marshall sold 50,232 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total transaction of $546,524.16. Following the completion of the sale, the general counsel now owns 245,638 shares in the company, valued at $2,672,541.44. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, General Counsel Tyson Eliot Marshall sold 50,232 shares of Alphatec stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total transaction of $546,524.16. Following the completion of the sale, the general counsel now directly owns 245,638 shares of the company’s stock, valued at approximately $2,672,541.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO John Todd Koning sold 37,500 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total value of $480,750.00. Following the completion of the transaction, the chief financial officer now directly owns 393,356 shares in the company, valued at $5,042,823.92. The disclosure for this sale can be found here. Insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ATEC. Townsquare Capital LLC boosted its stake in shares of Alphatec by 92.4% in the third quarter. Townsquare Capital LLC now owns 79,591 shares of the medical technology company’s stock valued at $1,032,000 after buying an additional 38,216 shares during the period. Tudor Investment Corp Et Al grew its holdings in shares of Alphatec by 80.8% during the 3rd quarter. Tudor Investment Corp Et Al now owns 244,189 shares of the medical technology company’s stock worth $3,167,000 after purchasing an additional 109,112 shares in the last quarter. Invst LLC increased its position in shares of Alphatec by 15.0% in the third quarter. Invst LLC now owns 152,919 shares of the medical technology company’s stock worth $1,983,000 after purchasing an additional 20,000 shares during the period. Walleye Capital LLC raised its stake in Alphatec by 13.1% in the third quarter. Walleye Capital LLC now owns 795,525 shares of the medical technology company’s stock valued at $10,318,000 after purchasing an additional 92,174 shares in the last quarter. Finally, Walleye Trading LLC lifted its position in Alphatec by 5.0% during the third quarter. Walleye Trading LLC now owns 50,353 shares of the medical technology company’s stock worth $653,000 after purchasing an additional 2,375 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.